[go: up one dir, main page]

KR970703353A - 단핵구 주화성 단백질-4(monocyte chemotactic protein-4) - Google Patents

단핵구 주화성 단백질-4(monocyte chemotactic protein-4)

Info

Publication number
KR970703353A
KR970703353A KR1019960706480A KR19960706480A KR970703353A KR 970703353 A KR970703353 A KR 970703353A KR 1019960706480 A KR1019960706480 A KR 1019960706480A KR 19960706480 A KR19960706480 A KR 19960706480A KR 970703353 A KR970703353 A KR 970703353A
Authority
KR
South Korea
Prior art keywords
polypeptide
polynucleotide
mcp
dna
patient
Prior art date
Application number
KR1019960706480A
Other languages
English (en)
Inventor
리 하오동
루벤 스티브
서튼 3세 그레인저 지
Original Assignee
로버트 에이치. 벤슨
휴먼 제놈 사이언시즈 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로버트 에이치. 벤슨, 휴먼 제놈 사이언시즈 인코오포레이티드 filed Critical 로버트 에이치. 벤슨
Publication of KR970703353A publication Critical patent/KR970703353A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

본 발명은 폴리펩티드 MCP-4, 이것을 암호화하는 폴리뉴클레오티드, 상기 폴리펩티드에 대한 항체 및 길항물질/억제제, 및 폴리펩티드 및 길항물질/억제제를 종양, 상처, 기생충 감염, 조혈의 조절, 염증, 류마티스성 관절염, 폐렴, 알레르기, 아테롬성 동맥경화증 및 결핵과 같은 전염성 질병의 치료용 약제로서 사용하는 방법에 관한 것이다.

Description

단핵구 주화성 단백질-4(MONOCYTE CHEMOTACTIC PROTEIN-4)
[도면의 간단한 설명]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (22)

  1. (a) 제1도의 추론된 아미노산 서열을 가진 MCP-4 폴리펩티드, 또는 이 폴리펩티드의 단편, 유사체 또는 유도체를 암호화하는 폴리뉴클레오티드; (b) ATCC 수탁번호 제75703호에 포함된 cDNA가 암호화하는 아미노산 서열을 가진 MCP-4 폴리펩티드, 또는 이 폴리펩티드의 한편, 유사체 또는 유도체를 암호화하는 폴리뉴클오티드로 이루어진 군에서 선택되는 분리된 폴리뉴클레오티드.
  2. 제1항에 있어서, 폴리뉴클레오티드가 DNA인 폴리뉴클레오티드.
  3. 제1항에 있어서, 폴리뉴클레오티드가 RNA인 폴리뉴클레오티드.
  4. 제1항에 있어서, 폴리뉴클레오티드가 게놈 DNA인 폴리뉴클레오티드.
  5. 제2항에 있어서, 상기 폴리뉴클레오티드가 제1도의 추론된 아미노산 서열을 가진 MCP-4를 암호화하는 폴리뉴클레오티드.
  6. 제2항에 있어서, 상기 폴리뉴클레오티드가 ATCC 수탁번호 제75703호의 cDNA가 암호화하는 MCP-4 폴리펩티드를 암호화하는 폴리뉴클레오티드.
  7. 제1항에 있어서, 제1도에 도시한 MCP-4의 암호 서열을 가진 폴리뉴클레오티드.
  8. 제2항에 있어서, ATCC 수탁번호 제75703호로 기탁된 MCP-4의 암호 서열을 가진 폴리뉴클레오티드.
  9. 제2항의 DNA를 함유하는 벡터.
  10. 제9항의 벡터를 사용하여 유전자 조작한 숙주 세포.
  11. 제10항의 숙주 세포로부터 상기 DNA가 암호화하는 폴리펩티드를 발현시키는 단계를 포함하는 폴리펩티드의 생산 방법.
  12. 제9항의 벡터를 사용하여 세포의 유전자를 조작하는 단계를 포함하는, 폴리펩티드를 발현시킬 수 있는 세포의 생산 방법.
  13. 제2항의 DNA에 혼성화가능하고 MCP-4 활성을 가진 폴리펩티드를 암호화하는 분리된 DNA.
  14. (i) 제1도의 추론된 아미노산 서열을 가진 MCP- 폴리펩티드, 및 이 폴리펩티드의 단편, 유사체 및 유도체 및 (ii) ATCC 수탁번호 제75703호의 cDNA가 암호화하는 MCP-4 폴리펩티드, 및 이 폴리펩티드의 단편, 유사체 및 유도체로 이루어진 군에서 선택되는 폴리펩티드.
  15. 제14항에 있어서, 폴리펩티드가 제1도의 추론된 아미노산 서열을 가진 MCP-4인 폴리펩티드.
  16. 제14항의 폴리펩티드에 대한 항체.
  17. 제14항의 폴리펩티드에 대한 작용물질(agonist).
  18. 제14항의 폴리펩티드에 대한 길항물질/억제제.
  19. 제14항의 폴리펩티드를 치료학적 유효량으로 환자에게 투여하는 단계를 포함하는 MCP-4를 필요로 하는 환자의 치료 방법.
  20. 제18항의 길항물질/억제제를 치료학적 유효량으로 환자에게 투여하는 단계를 포함하는 MCP-4를 억제할 필요가 있는 환자의 치료 방법.
  21. 제14항의 폴리펩티드 및 약학적 허용 담체를 함유하는 약학 조성물.
  22. 제19항에 있어서, 치료학적 유효량의 폴리펩티드는 환자에게 상기 폴리펩티드를 암호화하고 생체내에서 그 폴리펩티드를 발현시킬 수 있는 DNA를 제공하므로써 투여하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960706480A 1994-05-16 1994-05-16 단핵구 주화성 단백질-4(monocyte chemotactic protein-4) KR970703353A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1994/005384 WO1995031467A1 (en) 1994-05-16 1994-05-16 Monocyte chemotactic protein-4

Publications (1)

Publication Number Publication Date
KR970703353A true KR970703353A (ko) 1997-07-03

Family

ID=22242565

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960706480A KR970703353A (ko) 1994-05-16 1994-05-16 단핵구 주화성 단백질-4(monocyte chemotactic protein-4)

Country Status (9)

Country Link
EP (1) EP0767796B1 (ko)
JP (1) JP3670665B2 (ko)
KR (1) KR970703353A (ko)
AT (1) ATE206162T1 (ko)
AU (1) AU695174B2 (ko)
DE (1) DE69428460T2 (ko)
NZ (1) NZ266979A (ko)
PT (1) PT767796E (ko)
WO (1) WO1995031467A1 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2171761C (en) * 1993-09-14 2011-11-15 Timothy John Williams Eotaxin: eosinophil chemotactic cytokine
US6100389A (en) 1995-04-21 2000-08-08 Human Genome Sciences, Inc. Polynucleotides encoding a human chemotactic protein
US5866373A (en) * 1995-04-21 1999-02-02 Human Genome Sciences, Inc. Polynucleotide encoding a human chemotactic protein
US6075124A (en) * 1994-05-16 2000-06-13 Human Genome Sciences, Inc. Human chemotactin protein
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US6391589B1 (en) 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
US6537764B1 (en) 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
AU7735696A (en) * 1995-11-15 1997-06-05 Incyte Pharmaceuticals, Inc. Chemokine from niddm pancreas
EP0885293B1 (en) * 1996-02-23 2006-06-07 Human Genome Sciences, Inc. Human chemokine polypeptides
GB9617923D0 (en) * 1996-08-28 1996-10-09 Smithkline Beecham Plc Novel receptor
US6028169A (en) 1997-03-31 2000-02-22 Human Genome Sciences, Inc. Chemokine β-6 antagonists
DK0969877T3 (da) * 1997-04-04 2003-03-24 Max Planck Gesellschaft Fremgangsmåder til modulering af væksten af collaterale arterier og/eller andre arterier fra forudeksisterende arteriolære forbindelser
DE10162869A1 (de) * 2001-12-20 2003-07-31 Alexander Cherkasky Invasive lineare halb-zyklische und zyklische Systeme zur Herauslockung der Krankheitserreger
ATE518884T1 (de) 2002-05-01 2011-08-15 Human Genome Sciences Inc Spezifisch an chemokin beta-4 bindende antikörper
TWI589587B (zh) 2010-11-19 2017-07-01 衛材Ｒ＆Ｄ企管股份有限公司 中和性抗－ｃｃｌ２０抗體

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2669930A1 (fr) * 1990-11-29 1992-06-05 Sanofi Sa Proteine presentant une activite de type cytokine, adn recombinant, vecteur d'expression et hotes permettant son obtention.

Also Published As

Publication number Publication date
EP0767796A4 (en) 1997-06-11
NZ266979A (en) 1999-01-28
DE69428460D1 (de) 2001-10-31
EP0767796A1 (en) 1997-04-16
AU695174B2 (en) 1998-08-06
WO1995031467A1 (en) 1995-11-23
AU6913094A (en) 1995-12-05
JPH10500300A (ja) 1998-01-13
ATE206162T1 (de) 2001-10-15
DE69428460T2 (de) 2002-05-23
EP0767796B1 (en) 2001-09-26
PT767796E (pt) 2002-03-28
JP3670665B2 (ja) 2005-07-13

Similar Documents

Publication Publication Date Title
KR970703353A (ko) 단핵구 주화성 단백질-4(monocyte chemotactic protein-4)
Bhardwaj et al. IL-6/IFN-beta 2 in synovial effusions of patients with rheumatoid arthritis and other arthritides. Identification of several isoforms and studies of cellular sources.
KR970701776A (ko) 형질전환 성장 인자 알파 에이치1(Transforming growth factor alpha H1)
Cucina et al. Nicotine-induced smooth muscle cell proliferation is mediated through bFGF and TGF-β1
KR970705405A (ko) 사람 케모킨 폴리펩타이드(Human Chemokine Polypeptides)
KR970707141A (ko) 종양 괴사 인자-감마(Tumor necrosis factor-gamma)
KR920703819A (ko) 포유류 사이토긴, il-11
JPH01503354A (ja) Ｉｌ‐６の製造および用途
DE69433666D1 (de) ENTZÜNDUNGSPROTEINE AUS MAKROPHAGEN MIP-3, MIP-4 UND MIP-1Gamma
ATE185149T1 (de) Immunogene verbindungen mit spezifischem anti- cytokin effekt, methode zur herstellung, pharmazeutische zusammensetzung und reaktionskit der diese enthält
KR970705635A (ko) 사람 케모킨 베타-9(Human chemokine beta-9)
KR970701724A (ko) 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin)
ATE332379T1 (de) Menschliche dnase resistent gegen actininhibitoren
JPH0272869A (ja) 細胞増殖抑制因子
JP2863265B2 (ja) インターロイキン１インヒビター
CN1469756A (zh) 治疗肝病的药物
EP0969859A1 (en) The use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of tumor necrosis factor (tnf)
UA66749C2 (en) Actin-resistant variants of human dnase i, isolated nucleic acid, a method for treatment of patients suffering from pulmonary diseases
EE9900464A (et) Kõhre maatriksi oligomeerse valgu kasutamine reumatoidartriidi raviks
PT907737E (pt) Muteina da il-6
Camp Polypeptide neutrophil chemoattractants in the skin
MXPA99008721A (en) The use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of tumor necrosis factor (tnf)
Vasunia Role of epidermal cytokines in tumor promotion
CA2242562A1 (en) Human dnase resistant to actin inhibition

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19961115

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19990514

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20010629

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20030923

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20010629

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I